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Chun-Jun Li1,2, Jing-Yun Zhang1,2, De-Min Yu1,2* and Qiu-Mei Zhang1,2*Abstract
Background: To observe the efficacy and safety of adding glimepiride to established insulin therapy in poorly
controlled type 2 diabetes (T2D) and to assess the relationship of changes in the serum high-molecular weight
(HMW) adiponectin levels and glycemic control after glimepiride treatment.
Methods: Fifty-six subjects with poorly controlled insulin-treated T2D were randomly assigned to either the
glimepiride-added group (the group A, n = 29) or the insulin-increasing group (the group B, n = 27) while
continuing current insulin-based therapy. Glycosylated hemoglobin (HbA1c) value, daily insulin dose, body weight,
waist circumference, plasma lipid concentration, serum HMW adiponectin level and the number of hypoglycemic
events were evaluated before and after treatment.
Results: At the end of study, insulin doses were significantly reduced, and the mean HbA1c, fasting blood glucose
(FBG) and 2-hour postprandial blood glucose (P2BG) were improved greater in the group A compared with the
group B. The serum HMW adiponectin levels were significantly increased in the group A compared with the group
B. Most importantly, we found that changes in HbA1c were inversely correlated with changes in serum HMW
adiponectin in the group A (r = −0.452, p = 0.02).
Conclusions: Adding glimepiride to current insulin treatment led to better improvement in glycemic control with a
significant smaller daily insulin dose, and the increases in the serum HMW adiponectin levels may directly
contribute to improvement glycemic control.
Keywords: Glimepiride, Insulin therapy, HMW adiponectin, Type 2 diabetesIntroduction
Tight glycemic control with either intensive insulin ther-
apy or sulfonylurea has been associated with weight gain
in patients with type 2 diabetes (T2D) [1,2]. Achieving
glycemic control is a critical metabolic goal because
hyperglycemia contributes to the progression of T2D by
adversely affecting both β-cell function and insulin sensi-
tivity [3]. In clinical practice, achieving sustained glycemic* Correspondence: li_chunjun@126.com; zhzhzhtj@126.com
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unless otherwise stated.lowering over time is an important aspect of therapy that
is not achieved in many patients treated with large dosage
of exogenous insulin combination with non-sulfonylurea
drugs [4]. In addition, new treatment paradigm, aimed at
reducing insulin resistance may represent a more effective
treatment to decrease insulin dose. Unfortunately, most of
the insulin sensitizers such as thiazolidinediones (TZDs)
are associated with chronic heart failure [5]. Increasing
the insulin doses or changing the insulin regimen to mul-
tiple injections of insulin could improve glycemic control.
However, both endogenous hyperinsulinaemia and ex-
ogenous insulin could increase the risk of atherosclerosis
and cancer [6], meanwhile some physicians have concernshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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treatment [7].
Glimepiride, a third-generation sulfonylurea (SU), ex-
erts its effects mainly by stimulating insulin secretion
but has also been shown to have extrapancreatic effect
such as improvement insulin resistance [8]. Low level of
adipnectin was associated with insulin resistance, obes-
ity, and T2D [9]. Adiponectin is specifically and abun-
dantly expressed in adipose tissue and directly sensitizes
the body to insulin, which exists as three forms: a trimer
of low molecular weight, a hexamer of medium molecu-
lar weight and a larger multimeric high molecular weight
(HMW) form [10]. Glimepiride is reported to increase
adiponectin gene expression in adipocytes [11]. And sev-
eral studies have also demonstrated that glimepiride may
increase in insulin sensitivity associated with increased
serum adiponectinemia [12-14]. The HMW adiponectin
has been the active form of the hormone and has rele-
vant role in enhancing insulin sensitivity and in protect-
ing against diabetes [15]. Recently, several studies have
observed pioglitazone therapy significantly improving
glycemic control and markedly increasing serum HMW
adiponectin levels in T2D [16,17]. However, it is still un-
clear whether glimepiride treatment in T2D patients
could increase serum HMW adiponectin level to improve
glycemic control. And limited studies have reported that
combination therapy with glimepiride and insulin could
improve glycemic control and reduce insulin requirements
[18,19], but the mechanisms are not clear. Therefore, the
present study was conducted to analyze the relationship
between the degree of lowering HbA1c and serum HMW
adiponectin levels and provide predictors of which pa-
tients would benefit from addition glimepiride in poorly
controlled T2D subjects with insulin therapy.
Materials and methods
This study was undertaken in the out-patient setting of
the Metabolic Disease Hospital of Tianjin Medical Uni-
versity. Subjects eligible for the study met the following
criteria: T2D was defined by Chinese Diabetes Associ-
ation and HbA1c exceeding 8% treated by large dosage
of insulin (daily insulin dose more than 40 units) for at
least 6 months. Subjects were excluded if they had hep-
atic injury (serum alanine or aspartate aminotransferase
2.5 of more times the upper-normal range), or congest-
ive heart failure (NYHA Class III or IV) or renal damage
(serum creatinine above 2.0 mg/dl), and those already
receiving sulfonylureas or insulin sensitizers such as
TZDs within 6 months prior to the recruitment. Eli-
gible subjects were explained the goals and risk of the
study and gave their written informed consent before
beginning the study. The study protocol was approved
by the Tianjin Medical University Ethics Committee
Review Board and was conducted in accordance withthe Declaration of Helsinki and Good Clinical Practice
guidelines. Fifty-six subjects with T2D were randomly
assigned into either the glimepiride-added group (the
group A, n = 29) or the insulin-increasing group (the
group B, n = 27) while continuing based therapy.
HbA1c value, daily insulin dose, body weight, and the
number of hypoglycemic events were recorded at weeks 0,
12 and 24. Plasma lipid concentrations, serum C peptide
and HMW adiponectin concentration were measured at
weeks 0 and 24. The glycemic control target was defined as
fasting blood glucose (FBG) ≤ 7.0 mmol/L and 2-hour post-
prandial blood glucose (P2BG) ≤ 10 mmol/L. In the group
A, glimepiride (Amaryl, Sanofi aventis) was initiated at the
minimum dosage 1 mg once daily and then titrated up to
4 mg daily until the glycemic control target. In the group
B, insulin doses were increased to reach the glycemic con-
trol target. Hypoglycemic episodes and adverse events
(AEs) were recorded throughout the study. Hypoglycemia
was determined by the number of blood glucose readings
that were below 3.9 mmol/L, or occurrences of definite
hypoglycemic symptoms. Hypoglycemia was considered se-
vere when the event required third party assistance. Ad-
verse events were classified as serious if they resulted in
death, life-threatening experiences, hospitalization, or per-
sistant of significant disability or incapacity.
In addition, we have divided the group A subjects into
two sub-groups, according to the degree of HbA1c low-
ering (Responder, greater than 0.5% HbA1c lowering,
Non-responder, less than 0.5% HbA1c lowering). Plasma
total cholesterol, high-density lipoprotein (HDL) choles-
terol, and triglyceride concentrations were assessed using
standard enzymatic methods. HbA1c was assayed using
high-performance liquid chromatography. The HMW adi-
ponectin was measured with commercial ELISA Kit (R&D
Systems, USA).
Statistical analysis
Normally distributed data are expressed as mean ± stand-
ard deviation and non-normally distributed data median
or as numbers and percentages. Non-normally distributed
data were logtransformed for use with parametric statis-
tics. Unpaired t test was used to compare the differences
in clinical characteristics between groups at baseline and
after treatment assessed for significance using for the
discrete or continuous data and the chi-square test for fre-
quency distributions. The changes in HbA1c, FBG and
2 h-BG over time (at baseline and at the other 2 visits)
were studied using the repeated measurements ANOVA
with treatment as grouping factor. Paired t tests were used
to compare within-group changes. And unpaired t tests
were also used to compare baseline variables between Re-
sponders and Non-responders in subjects treated with
glimepiride-added. Linear regressions were performed to
determine relationships between changes in serum HMW
Table 1 Baseline characteristics of subjects in the 2
groups




Age (years) 56.8 ± 12.3 56.3 ± 12.4
Sex (Male/Female) 15/14 13/14
Body weight (kg) 66.2 ± 16.3 67.2 ± 15.9
BMI (kg/m2) 25.2 ± 3.6 25.4 ± 3.7
Waist Circumference (cm) 93.55 ± 10.5 93.46 ± 10.4
duration of diabetes (years) 15.6 ± 5.7 15.4 ± 6.2






α-glucosidase inhibitors(-/ +) 2/27 1/26
Metformin (−/ +) 13/16 14/13
Duration of insulin treatment (years) 9.6 ± 3.4 9.4 ± 3.5
Total insulin dose (unit/day) 68.6 ± 14.6 66.8 ± 13.9
Frequency of insulin injection (2-/3−/−4
times /d)
17/8/4 16/7/4
HbA1c (%) 9.3 ± 1.5 9.4 ± 1.4
FBG (mmol/L) 11.4 ± 2.4 11.3 ± 2.6
P2BG (mmol/L) 16.8 ± 4.4 17.0 ± 4.5
Triglyceride (mmol/L) 3.26 ± 1.14 3.28 ± 1.16
Total Cholesterol (mmol/L) 6.23 ± 1.41 6.19 ± 1.51
HDL-Cholesterol (mmol/L) 1.04 ± 0.23 1.12 ± 0.21
LDL-Cholesterol (mmol/L) 4.13 ± 1.01 4.20 ± 1.02
Serum C peptide (ng/ml) 1.06 ± 0.68 1.06 ± 0.70
HMW adiponectin (μg/ml) 3.12 ± 1.56 3.22 ± 1.54
Normally distributed data expressed as mean ± standard deviation and
non-normally distributed data expressed as median or as numbers and
percentages. Non-normally distributed data were log-transformed for use with
parametric statistics. BMI: body mass index; NDR: no diabetic retinopathy; SDR:
simple diabetic retinopathy; PDR: proliferative diabetic retinopathy; CVD:
cardiovascular disease; HbA1c: Glycosylated hemoglobin; FBG: fasting blood
glucose; P2BG: 2-hour postprandial blood glucose; LDL: low-density lipoprotein;
HMW adiponectin: high-molecular weight adiponectin.
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analyses were performed using SPSS windows version
18.0, and p value < 0.05 was considered to be statistical
significance.
Results
A total of 56 subjects with poorly controlled insulin-
treated T2D were recruited and completed the trial. At
baseline, the two groups did not differ regarding an-
thropometric data, duration of diabetes and insulin treat-
ment, BMI, waist circumference, body weight, HbA1c
value, FBG, P2BG, plasma lipid concentration, daily insu-
lin dose, frequency of insulin injections, combined anti-
diabetic agents, C-peptide concentration and HMW
adiponectin levels. Overall, the subjects had a long dur-
ation of diabetes and poor glycemic control with large
dosage of insulin. 75% of the subjects had abdominal obes-
ity defined by Chinese Diabetes Association (Male waist cir-
cumference ≥ 90 cm, Female waist circumference ≥ 85 cm).
A similar portion of subjects in the two groups were suffer-
ing from diabetic complications such as nephropathy, retin-
opathy and cardiovascular disease (Table 1).
During the study, mean values of HbA1c, FBG and
P2BG were significantly reduced in both groups (Table 2).
Repeated measurements of ANOVA on decreases in
HbA1c, FBG and P2BG over the time were significant
different between groups and greater in the group A
(p < 0.01). The primary efficacy endpoint, the reductions
in HbA1c of 2.0% from baseline in the group A was sig-
nificant greater than reductions of 1.6% in the group B
(p < 0.01). The target HbA1c level 7.0% achieved by 15
subjects (52%) in the group A was larger than 8 subjects
(30%) in the group B (p < 0.05). The required insulin doses
were reduced by 53% (from 68.6 ± 14.6 to 32.3 ± 14.9 unit/d)
in the group A, while it was increased by 29% (from
66.8 ± 13.9 to 86.2 ± 18.9 unit/d) in the group B, the differ-
ence is significant. Body weight was increased significantly
during the course of the study in the group B (from
67.2 ± 15.9 kg to 69.8 ± 16.5 kg, p <0.05); however, there
was no significant change in body weight in the group A
(from 66.2 ± 16.3 to 66.9 ± 16.6 kg, p > 0.05).
There were no significant changes in plasma triglycer-
ide, total cholesterol, LDL-cholesterol, HDL-cholesterol
and plasma C peptide in both groups. Serum HMW adi-
ponectin levels were markedly increased from (3.12 ±
1.56) μg/ml to (5.86 ± 1.62) μg/ml in the group A, while
no significant changes in the group B (Table 3). Changes
in HbA1c were inversely associated with changes in
serum HMW adiponectin in the group A (r = −0.452,
p = 0.02). Reinforcing this, when we stratified patients
into subgroups according to the degree of HbA1c lower-
ing ≥ 0.5% or 0.5%: the responder group (n = 23) and
the non-responder group (n = 6), there were significant
greater increases in the HMW adiponectin concentrationsin the responder group compared with the non-responder
group. In addition, there were higher levels of body
weight, waist circumference, HbA1c, FBG, total insulin
doses and lower HMW adiponectin concentrations in the
responder group compared with the non-responder group
at baseline (Table 4). However, a weak but significant lin-
ear correlation was found between the baseline HbA1c
values and changes in HbA1c after treatment (r = −0.38,
p = 0.04), and no significant correlation was found be-
tween baseline serum HMW adiponectin and changes in
HbA1c (r = 0.29, p = 0.15).
During the 24-week observation period, hypoglycemic
episodes were significantly lower in the group A than in the
group B (p < 0.05); Moreover, significantly fewer subjects in
Table 2 Assessment of treatments for efficacy in glycemic
control in the 2 groups
Variables 0 week 12 weeks 24 weeks
HbA1c (%)
The group A 9.3 ± 1.5 8.2 ± 1.2* 7.3 ± 1.3**
The group B 9.4 ± 1.4 8.6 ± 1.3* 7.9 ± 1.3*#
FBG (mmol/L)
The group A 11.4 ± 2.4 7.6 ± 1.8** 6.9 ± 1.3**
The group B 11.3 ± 2.6 8.2 ± 2.1** 7.7 ± 1.6**#
P2BG (mmol/L)
The group A 16.8 ± 4.4 11.2 ± 2.3** 8.6 ± 2.1**
The group B 17.0 ± 4.5 12.4 ± 2.3** 10.8 ± 2.2**#
Insulin dose (unit/day)
The group A 68.6 ± 14.6 44.8 ± 15.9** 32.3 ± 14.9**
The group B 66.8 ± 13.9 79.3 ± 14.8* 86.2 ± 18.9**##
Body Weight (kg)
The group A 66.2 ± 16.3 66.4 ± 16.5 66.9 ± 16.6
The group B 67.2 ± 15.9 68.3 ± 16.0 69.8 ± 16.5**#
Data expressed mean ± SD; HbA1c: Glycosylated hemoglobin; FBG: fasting
blood glucose; P2BG: 2-hour postprandial blood glucose; *p < 0.05 vs. baseline,
**p < 0.01 vs. baseline. #p < 0.05 group A vs. group B, ##p < 0.01 group A vs.
group B.
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sode. Despite the occurrence of hypoglycemic episodes
in the two groups, no episode was classified as severe,
requiring assistance. Moreover, no AE was recorded
during the study.
Discussion
In the present study, subjects with poorly controlled
T2D achieved significant mean reductions in the HbA1c,Table 3 Changes in outcome parameters after 24 weeks
treatment
Variable The group A (n = 29) The group B (n = 27)
Baseline 24 weeks Baseline 24 weeks
Triglyceride
(mmol/L)
3.26 ± 1.14 3.16 ± 1.12 3.28 ± 1.16 3.24 ± 1.15
Total Cholesterol
(mmol/L)
6.23 ± 1.41 6.18 ± 1.72 6.19 ± 1.51 6.17 ± 1.68
HDL-Cholesterol
(mmol/L)
1.04 ± 0.23 1.14 ± 0.38 1.12 ± 0.21 1.13 ± 0.24
LDL-Cholesterol
(mmol/L)
4.13 ± 1.01 3.67 ± 1.12 4.20 ± 1.02 3.81 ± 1.20
Serum C peptide
(ng/ml)
1.06 ± 0.68 1.18 ± 0.66 1.06 ± 0.70 1.10 ± 0.69
HMW adiponectin
(ug/ml)
3.12 ± 1.56 5.86 ± 1.62* 3.22 ± 1.54 3.24 ± 1.53##
Data expressed mean ± SD; LDL: low-density lipoprotein; HMW: high-molecular
weight; *p < 0.05 difference compared with baseline, ##p < 0.01 compared
absolute changes between the group A and group B following 24 weeks
glimepiride treatment.FBG and P2BG with glimepiride-added treatment com-
pared with increasing insulin doses. A significant higher
percentage of subjects (52%) in the group A had an
HbA1c goal of ≤ 7% at the end of study compared with
(30%) in the group B, reflecting the greater mean reduc-
tion in the HbA1c observed in the group A. Further-
more, adding glimepiride also remarkably decreased
insulin doses and offered clear advantages in terms of a
reduction in the incidence of hypoglycemia and no
weight gain. The most interesting findings reported here
were the significant correlations between HbA1c lower-
ing and increases in serum HMW adiponectin levels
following 24-week glimepiride treatment (r = −0.452, p =
0.02). We also found that serum HMW adiponectin
levels increased particularly more in patients who got
more than 0.5% reductions in HbA1c compared with pa-
tients who got less than 0.5%, suggesting the possible
role of increases in serum HMW adiponectin levels on
the glimepiride-induced glycemic control.
In practice, a significant number of subjects with
T2D cannot achieve tight glycemic control despite treat-
ment with large dosage insulin combination with non-
sulfonylurea drugs over time. Most of physicians are
reluctant to continue to increase insulin doses or to
carry out intensive insulin treatment due to the side
effects associated with insulin-induced hypoglycemia
and weight gain. Combinations of insulin with second-
generation sulfonylurea derivatives, such as glibencla-
mide and gliclazide, have been found to offer significant
improvement in glycemic control with a significantly
smaller daily insulin dose [20]. SU use with insulin works
because of the higher levels of insulin in the portal circula-
tion with SU, compared to subcutaneous insulin, lowers
hepatic glucose output and therefore fasting insulin better.
Although many SU agents have been administered suc-
cessfully with insulin, only glimepiride has been approved
by the United States Food and Drug Adiministration for
combination therapy. Moreover, only glimepiride has been
shown not to block the beneficial effect of myocardial is-
chemic preconditioning that glyburide and glipizide have
[21]. Furthermore, a large cohort study recently provided
the clinical evidence of a trend toward an increased overall
mortality risk with glyburide or glipizide versus glimepir-
ide in those with documented cardiovascular disease [22].
Therefore, we preferred to add glimepiride to the current
insulin therapy in the present study. Several clinical stud-
ies have supported that addition of glimepiride in the sub-
jects with poorly controlled insulin-treated type 2 diabetes
could improve glycemic control and reduce insulin re-
quirements [18,19]. However, the underlined mechanisms
are still not clear.
Insulin resistance has been the main reason for grad-
ual worsening of glycemic control in obese T2D subjects.
Obese T2D has become a big problem in Asian subjects,
Table 4 Changes in the responders and non- responder following 24 weeks treatment
Variables Responder group (n = 23) Non-responder group (n = 6)
Baseline 24 weeks Baseline 24 weeks
Body weight (kg) 66.8 ± 16.3 67.3 ± 17.4 62.4 ± 14.8* 64.3 ± 15.9
Waist Circumference (cm) 97.6 ± 12.2 98.0 ± 12.1 84.6 ± 85** 85.9 ± 8.4
Total insulin dose (units/day) 71.3 ± 14.9 32.1 ± 14.0 59.8 ± 12.9 ** 54.5 ± 14.7##
HbA1c (%) 9.5 ± 1.2 7.8 ± 1.1 8.6 ± 1.3* 8.4 ± 1.1##
FBG (mmol/L) 12.0 ± 2.7 7.4 ± 1.4 9.8 ± 2.1* 9.2 ± 1.5##
P2BG (mmol/L) 16.7 ± 4.8 9.8 ± 2.4 16.3 ± 4.2 15.8 ± 4.2##
HMW adiponectin (ug/ml) 2.89 ± 1.54 5.79 ± 1.58 4.74 ± 1.46** 5.11 ± 1.52##
Normally distributed data expressed as mean ± standard deviation and non-normally distributed data expressed as median or as numbers and percentages.
Non-normally distributed data were logtransformed for use with parametric statistics. HbA1c: Glycosylated hemoglobin; FBG: fasting blood glucose; P2BG: 2-hour
postprandial blood glucose; HMW: high-molecular weight; Data are mean ± SD. *p < 0.05 and **P <0.01 for responder vs. non-responder at baseline; #p<0.05 and
##p<0.01 for absolute changes in responder vs. non-responder following 24 weeks glimepiride treatment.
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pared with European and American subjects [23]. In our
study, 75% subjects with poorly controlled glycemia had
abdominal obesity with large dosage of insulin. In obese
subjects, circulating adiponectin concentrations inversely
correlate with visceral fat area, but not with BMI, and
subcutaneous fat area [24]. Reduction of visceral fat in-
creases circulating adiponectin levels in the general
population and obese individuals [8]. Several clinical tri-
als have shown that glimepiride could increase serum
adiponectin levels in T2D [12,13,25]. The HMW adipo-
nectin is the main active form of the hormone and has
relevant role in enhancing insulin sensitivity and protect-
ing against diabetes [15]. For the first time, the present
study demonstrated that glimepiride combination with
insulin therapy could markedly increase serum HMW
adiponectin levels in T2D subjects. We also found a sig-
nificant negative correlation between changes of HbA1c
and increases in HMW adiponectin levels following
24-week glimepiride treatment, suggesting that the greater
reduction in HbA1c is associated with the greater in-
creases in HMW adiponectin levels. This suggests that the
reduced glycemic effect of glimepiride may be mediated
through up-regulation and increased secretion of HMW
adiponectin by adipocytes [25]. Moreover, several studies
supported that insulin seems to suppress expression and
secretion of adiponectin both in vitro [26] and in vivo
studies [27], suggesting that the great reductions in insulin
dose by glimepiride treatment may conversely increase
plasma HMW adiponectin concentration. Nagasaka et al.
[13] suggest that the increase in adiponectinemia by the
glimepiride treatment could be, in part, due to an effect of
glycemic control. Therefore, the mechanisms of the in-
creased adiponectinemia by glimepiride may be complex
and multifactorial.
Hypoglycemia is the most important barrier associated
with anti-diabetic treatment. During the 24-week obser-
vation period, adding glimepiride treatment is associatedwith lower hypoglycemic episodes compared with increas-
ing insulin doses to the insulin-based therapy. Moreover,
67% of the subjects treated with increasing insulin doses
experienced at least one episode of hypoglycaemia, while
only 28% of the subjects with adding glimepiride experi-
enced at least one episode of hypogycaemia. Glimepiride
is widely used second-generation sulfonylurea purportedly
has lower risk of hypoglycaemia and weight gain relative
to other medications in the same class [28,29]. The risk of
hypoglycemia may be dose-dependent; the relationship
between dose and glycemic efficacy of sulfonylurea agents
was not linear over the therapeutic dose range. In a dose-
range finding study with glimepiride, a substantial reduc-
tion in HbA1c was observed with 1 mg daily, whereas
nearly full efficacy was reached with 4- mg/day dose with
an additional efficacy obtained by escalation through doses
of 8-mg/day [30]. Overall, clinical AE and drug-related
AEs were reported more frequently with higher doses
glimepiride.
Weight gain is another problem associated with insu-
lin treatment. As reported by the UKPDS, subjects with
T2D gained about 4 kg body weight after 10 years of in-
sulin treatment [2]. As expected, in the study, the mean
body weight was slightly increased in the group B after
24 weeks insulin administration. The gain in body weight
associated with insulin and sulfonylurea agents is an un-
desirable side effect in subjects with T2D. In the study,
we surprisingly found no significant weight gain with
glimepiride-added to insulin therapy, which maybe benefit
from remarkably decreased insulin doses. Obesity corre-
lates with diabetogenic, atherogenic, pro-thrombolic, and
pro-inflammatory metabolic CVDs, which increase the
risk of atherosclerotic CVD [23]. Even a slight increase
in body weight appears harmful, as it is associated with
increased mortality and serious comorbidities, such as
hypertension, hyperlipidemia, and CVD. Therefore, the
subjects in the group B seem to have greater risk of severe
metabolic abnormalities.
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In summary, we firstly showed in this study that adding
glimepiride led to better improvement in glycemic control
with a significant smaller daily insulin dose, especially in
the abdominal obese T2D subjects with lower HMW adi-
ponectin level before treatment. Most importantly, there
was a significant negative correlation between the increase
in the HMW adiponectin levels and changes in the HbA1c
following glimepiride treatment. And the HMW adipo-
nectin level increased particularly more in responder sub-
jects compared with non-responder subjects, suggesting
that increases in the serum HMW adiponectin level
may directly contribute to improvement glycemic con-
trol. A limitation of the study was the relatively small
sample size and would require further research to prove
our results.
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